Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, Inc. held its annual stockholder meeting, with 10,206,763 votes represented, equivalent to approximately 73.51% of outstanding voting power, establishing a quorum. Six directors were elected, each receiving at least 96.64% of votes cast for their seats.
Stockholders ratified the appointment of Rosenberg Rich Baker Berman, P.A. as independent auditor for the year ending December 31, 2026, with 10,187,191 votes in favor. They also approved an amendment to the 2022 Omnibus Securities and Incentive Plan, which again revised Section 5.1, and approved the Neuraxis, Inc. 2025 Employee Stock Purchase Plan.
Before the meeting, the board amended Section 5(c) of the Employee Stock Purchase Plan so that no employee may receive purchase rights if, immediately after grant, the employee would own 10% or more of the company’s voting power or value, replacing the original 5% limitation.
NeurAxis, Inc. reported strong top-line growth but continued losses in its quarter ended March 31, 2026. Net sales rose to $1,607,883 from $895,655 a year earlier as adoption of its IB-Stim neuromodulation device increased following a Category I CPT code and broader insurance coverage. Gross margin improved to 86.4%, but the company still posted a net loss of $1,761,432, though smaller than the prior-year loss of $2,278,684.
Cash and cash equivalents increased to $7,078,659 and working capital to $5,328,867, helped by $2,990,361 of common stock sales under an at-the-market program and warrant exercises. Stockholders’ equity was $5,747,550. Despite these improvements, management and auditors concluded that substantial doubt exists about NeurAxis’s ability to continue as a going concern, given ongoing operating losses and reliance on future capital raises and wider insurance coverage.
The company carries Series B preferred stock with cumulative undeclared dividends of $1,215,264 and maintains warrant liabilities of $48,306. It also continues to remediate material weaknesses in internal control over financial reporting and is making installment payments on a $750,000 litigation settlement.
Neuraxis, Inc. ownership update: Bigger Capital Fund, LP and affiliated parties report beneficial holdings in Common Stock. As of May 1, 2026, Bigger Capital beneficially owned 755,577 shares. The filing notes a 4.99% beneficial ownership limitation on certain warrants.
The filing states shares outstanding were 11,505,421 as of April 20, 2026 per the issuer's prospectus. Related entities and Michael Bigger disclose shared voting and dispositive power and additional warrant positions that are subject to the stated ownership limitation.
Neuraxis (NRXS) director Aharon Gil reported stock awards tied to preferred share dividends rather than open‑market trading. On April 28, 2026, entities associated with him acquired 221,917 shares of common stock indirectly through Rosalind Master Fund L.P. and 12,304 shares directly.
These shares were issued as dividends on Series B Preferred Stock, calculated by dividing accrued and unpaid 8.5% cumulative dividends by $2.38 per share. Following the transactions, Gil’s reported holdings total 508,055 indirect shares and 33,902 direct shares of Neuraxis common stock.
Neuraxis, Inc. is calling a 2026 annual stockholder meeting on June 10, 2026 to elect six directors and conduct key governance votes. Holders of 11,505,421 shares of Common Stock and 3,796,907 shares of Series B Preferred Stock as of April 14, 2026 may vote, with total voting power of 13,883,480 votes.
The board asks stockholders to ratify Rosenberg Rich Baker Berman, P.A. as auditor, expand the 2022 Omnibus Securities and Incentive Plan from 1,482,152 to 3,400,000 authorized shares and extend its evergreen feature to 2033, approve a 2025 Employee Stock Purchase Plan, and allow potential adjournment to solicit additional proxies.
Neuraxis, Inc. increased the capacity of its existing at-the-market stock offering program. The company may now sell shares of its common stock for an aggregate offering price of up to $11,500,000 through Craig-Hallum Capital Group LLC under a previously effective Form S-3 shelf registration.
The agreement was originally sized at up to $6,270,000. From August 29, 2025 through April 20, 2026, Neuraxis sold 1,125,281 shares of common stock under this arrangement. A new prospectus supplement and a related legal opinion from Lucosky Brookman LLP support the expanded program.
Neuraxis, Inc. released preliminary, unaudited figures for the quarter ended March 31, 2026. The Company expects cash and cash equivalents of about $7.1 million as of that date, providing a snapshot of its available liquidity.
For the same three-month period, Neuraxis anticipates net sales of approximately $1.6 million, up from about $0.9 million a year earlier, showing strong year-over-year revenue growth. On a preliminary basis, it expects gross profit of about $1.4 million and an operating loss of about $1.7 million, indicating the business is still not profitable.
The Company emphasizes these numbers are preliminary and unaudited and may change as the quarter-end close is completed and the independent registered public accounting firm reviews the full financial statements.
Neuraxis, Inc. amends its prospectus supplement to increase its at-the-market offering capacity to up to $11,500,000 of Common Stock to be sold from time to time through Craig-Hallum Capital Group LLC under an existing Sales Agreement.
The supplement states the company sold $5.8 million of securities under the Sales Agreement from August 29, 2025 through April 20, 2026. Preliminary unaudited results show cash and cash equivalents of approximately $7.1 million as of March 31, 2026, net sales of about $1.6 million for the three months ended March 31, 2026 (versus $0.9 million for the comparable prior-year period), preliminary gross profit of $1.4 million, and a preliminary operating loss of $1.7 million for that quarter. The filing discloses a public float of $66,876,930 based on 11,505,421 shares outstanding as of April 20, 2026.
Neuraxis, INC Chief Financial Officer buys company stock in open market trade. On April 1, 2026, CFO Timothy Robert Henrichs purchased 7,593 shares of Neuraxis common stock in an open-market transaction at a price of $1.96 per share. Following this purchase, he directly owns 7,593 shares.